James Song, MD, FAAD, Director of Clinical Research at Frontier Dermatology, discusses the severity of Generalized Pustular Psoriasis (GPP) and the role of targeted systemic therapy in managing this life-threatening inflammatory condition.
GPP can cause widespread pustules, systemic inflammation, and disruption of the skin barrier, often requiring hospitalization due to risks such as infection, dehydration, and potential organ complications. Dr. Song highlights the emerging role of Spesolimab, a targeted therapy designed to inhibit the dysregulated Interleukin-36 pathway, which plays a key role in the inflammatory cascade driving GPP.
Topics Covered
- The severity and systemic risks associated with generalized pustular psoriasis
- How IL-36 pathway dysregulation contributes to disease progression
- Clinical trial results demonstrating the effectiveness of spesolimab in reducing pustules
- Treatment strategies using intravenous dosing for acute flares and subcutaneous dosing for maintenance therapy
- Addressing systemic symptoms such as fatigue, pain, and joint involvement
Explore Related Resources
Advancements in the Management Paradigm for Generalized Pustular Psoriasis
Raising Awareness for Generalized Pustular Psoriasis
